0
Views
2
CrossRef citations to date
0
Altmetric
Invited communication

Nutrition in paediatric Crohn’s disease

Pages 33-36 | Published online: 31 May 2016

References

  • Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn’s disease. Nat Rev Gastroenterol Hepatol. 2009;6:513–23.
  • Sentongo TA, Semeao EJ, Piccoli DA, Stallings V A, Zemel BS. Growth, body composition and nutritional status in children and” adolescents with Crohn’s disease. J Pediatr Gastroenterol Nutr 2000;31:33–40.
  • Savage MO, Eeattie RM, Caillacho-Hubner C, Walker-Sillith JA, Sanderson IR. Growth in Crohn’s disease. Acta Paediatr Suppl 1999;88:89–92.
  • Motil KJ, Grand RJ, Maletskos CJ, Young VR. The effect of disease, drug and diet on whole body protein metabolism in adolescents with Crohn disease and growth failure. J Pediatr 1982;101:345–51,
  • Thomas AG, Miller V, Taylor F, et al. Whole body protein turnover in childhood Crohn’s disease. Out 1992;33:675–7.
  • Zoli G, Katelaris PH, Garrow J, et al. Increased energy expenditure in growing adolescents with Crohn ‘s disease. Dig Dis Sci 1996;41:1754–9.
  • Varille V, Cézard JP, de Lagausie P, et al. Resting energy expenditure before and after surgical resection of gut lesions in pediatric Crohn ‘ s disease. J Pediatr Gastroenterol Nutr 1996;23:13–9.
  • Mingrone G, Capristo E, Greco A V, et al. Elevated diet-induced therrnogenesis and lipid oxidation in Crohn disease. Am J Clin Nutr 1999;69:325–30.
  • Wiskin AE, Wootton SA, Culliford DJ, Afzal NA, Jackson AA, Beattie RM. Impact of disease activity on resting energy expenditure in children with inflammatory bowel disease. Clin Nutr. 2009 Jun 8. [Epub ahead of print]
  • Nishi Y, Lifshitz F, Eayne MA, et al. Zinc status and its relation to growth retardation in children with inflamrnatory bowel disease. Am J Clin Nutr 1980;33:2613–21.
  • Rannem T, Ladefoged K, Hylander E, et al. Selenium status in patients with Crohn’s disease, Am J Clin Nutr 1992;56:933–7.
  • Levine A, Shamir R, Wine E, Weiss B, Karban A, Shaoul RR, et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn’s disease. Am J Gastroenterol. 2005;100:1598–604.
  • Wong SC, Macrae VE, McGrogan P, Ahmed SF. The role of pro-inflammatory cytokines in inflammatory bowel disease growth retardation. J Pediatr Gastroenterol Nutr. 2006;43:144–55.
  • Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJ. Growth failure occurs through a decrease in insulin-like growth factor 1 which is independent of undernutrition in a rat model of colitis. Gut. 2000;46:694–700.
  • Sawczenko A, Azooz O, Paraszczuk J, Idestrom M, Croft NM, Savage MO, Ballinger AB, Sanderson IR. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc Natl Acad Sci U S A. 2005;102:13260–5.
  • De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology. 2001;142:4818–26.
  • Newby EA, Sawczenko A, Thomas AG, Wilson D. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003873.
  • Navarro FA, Hanauer SB, Kirschner BS. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease. J Pediatr Gastroenterol Nutr. 2007;45:312–8.
  • Semeao El, Jawad AF, Stouffer NO, Zemel BS, Piccoli DA, Stallings VA. Risk factors for low bone mineraI density in children and young adults with Crohn’s disease. J Pediatr 1999;135:593–600.
  • O’Morain C, Segal A W, Levi AJ, Valman HB. Elemental diet in acute Crohn’s disease. Arch Di.s. Child 1983;53:44– 7.
  • Griffiths AM, Oh1sson A, Sherrnan PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment ofactive Crohn’s disease. Gastroenterology 1995;108:1056–67.
  • Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of active Crohn’s disease. Gastroenterology 1995;108:1056–67.
  • Griffiths AM. Enteral nutrition: the neglected primary therapy of active Crohn’s disease. J Pediatr Gastroenterol Nutr 2000;31:3–5.
  • Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn’s disease. Cochrane Database Syst Rev. 2001;(3):CD000542.
  • Escher JC, Taminiau JA, Nieuwenhuis EE, Büller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis. 2003;9:34–58.
  • Ruemmele FM, Roy CC, Levy E, Seidman EG. Nutrition as primary therapy in pediatric Crohn’s disease: fact or fantasy ? J Pediatr 2000; 136:285–91.
  • Heuschkel RB, Walker-Smith JA. EnteraI nutrition in inflammatory bowel disease of childhood. JPEN 1999;23: S29–S32.
  • Teahon K, Smethurst P, Pearson M, et al. The effect of elemental diet on intestinal permeability and inflammation in Crohn’s disease. Gastroenterology 1991;101:84–9.
  • Beattie RM, Schiffin EJS, Donnet-Hughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn ‘s disease. Aliment Pharmacol Therap 1994;8:609–15.
  • Breese EJ, Michie CA, Nicholls SW, et al. The effect of treatment of lymphokine-secreting cells in the intestinal mucosa of children with Crohn’s disease. Aliment Pharmacol Therap 1995;9:547–53.
  • Fell JM, Paintin M, Donnet-Hughes A, Arnaud-Battandier F, MacDonald TT, Walker-Smith JA. Remission induced by a new specific oral polymeric diet in children with Crohn’s disease. Nestle Nutr Workshop Ser Clin Perform Programme. 1999;2:187–96.
  • Belluzi A, Brignola C, Campieri M, et al. Effect of an enteric coated fish-oil preparation on relapses in Crohn’s disease. N EnglJ Med 1996;334:1557–60.
  • Hartman C, Berkowitz D, Weiss B, Shaoul R, Levine A, Adiv OE, et al. Nutritional supplementation with polymeric diet enriched with transforming growth factor-beta 2 for children with Crohn’s disease. Isr Med Assoc J. 2008;10:503–7.
  • Rubio A, Talbotec C, Garnier H, Schmitz J, Syhan J, Goulet O, Ruemmele F. Efficacy of fractioned oral vezrsus continuous enteral nutritional therapy in pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 2009; (Abstract)
  • Lionetti P, Callegari ML, Ferrari S, Cavicchi MC, Pozzi E, de Martino M, Morelli L. Enteral nutrition and microflora in pediatric Crohn’s disease. JPEN J Parenter Enteral Nutr. 2005;29(4 Suppl):S173–5.
  • Leach ST, Mitchell HM, Eng WR, Zhang L, Day AS. Sustained modulation of intestinal bacteria by exclusive enteral nutrition used to treat children with Crohn’s disease. Aliment Pharmacol Ther. 2008 Sep 15;28(6):724–33.
  • Buchanan E, Gaunt WW, Cardigan T, Garrick V, McGrogan P, Russell RK. The use of exclusive enteral nutrition for induction of remission in children with Crohn’s disease demonstrates that disease phenotype does not influence clinical remission. Aliment Pharmacol Ther. 2009 1;30:501–7.
  • Weiss B, Lebowitz O, Fidder HH, Maza I, Levine A, Shaoul R, Reif S, Bujanover Y, Karban A. Response to Medical Treatment in Patients with Crohn’s Disease: The Role of NOD2/CARD15, Disease Phenotype, and Age of Diagnosis. Dig Dis Sci. 2009 Aug 20. [Epub ahead of print]
  • Yamamoto T, Nakahigashi M, Umegae S, Matsumoto K. Enteral nutrition for the maintenance of remission in Crohn’s disease: a systematic review. Eur J Gastroenterol Hepatol. 2009 Aug 24. [Epub ahead of print]
  • Greenberg OR, Fleming CR, Jeejeebhoy KN, et al. Controlled trial of bowel rest and nutritional support in the management of Crohn’s disease. Gut 1988;29:1309–15.
  • Layden T, Rosenberg l, Nemchausky B, et al. ReversaI of growth arrest in adolescents with Crohn’s disease after parenteral alimentation. Gastroenterology 1976;70:1017 –21.
  • Strobel CT, Byme Wl, Ament ME. Home parenteral nutrition in children with Crohn’s disease: an effective management alternative. Gastroenteroiogy 1979;77: 272–9.
  • Lake AM, Kim S, Mathis RK, Walker W A. Influence of preoperative parenteral alimentation on postoperatirve growth in adolescent Crohn’s disease. J Pediatr Gastroenterol Nutr 1985;4:182–6
  • Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, et al. Natural history of pediatric Crohn’s disease: a population-based cohort study. Gastroenterology. 2008;135:1106–13.
  • Feagan BG, Fedorak RN, Irvine J, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. N Engl J Med 2000 ;342:1627–320.
  • Lloyd Still JD. Azathioprine and the treatment of chronic inflammatory bowel disease. J Pediatr 1990; 117: 732–5.
  • Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117:809–14.
  • Markowitz J, Grancher K, Kohn N, Lesser M, Daum F and the pediatric 6MP collaborative group. A multicenter trial of 6-mercaptopurine and prednisone In children with newly diagnosed Crohn’s disease. Gastroenterology 2000;119:895–902.
  • Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis. 2007 4:424–30.
  • Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, et al. Growth abnormalities persist in newly diagnosed children with crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr. 2009;48:168–74.
  • McLain BI, Davidson PM, Stokes KB, Beasley SW. Growth after gut resection for Crohn’s disease. Arch Dis Child 1991;65:370–6.
  • Wong SC, Hassan K, McGrogan P, Weaver LT, Ahmed SF.The effects of recombinant human growth hormone on linear growth in children with Crohn’s disease and short stature. J Pediatr Endocrinol Metab. 2007;20:1315–24.
  • Heuschkel R. Enteral nutrition should be used to induce remission in childhood Crohn’s disease. Dig Dis. 2009;27:297–305.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.